Pregnancy Loss Between 15 and 22 Weeks SA Within the Network of Perinatal Pérriodof Western Brittany : Case Control Study PILOT STUDY CA
NCT ID: NCT03668743
Last Updated: 2018-09-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
202 participants
OBSERVATIONAL
2017-06-01
2017-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antenatal Detection of Fetal Growth Restriction and Stillbirths Rate.
NCT01995968
Study of Late Fetal Loss in Poitou-Charentes. GYNE-COVID
NCT04387253
Hydroxychloroquine for Prevention of Recurrent Miscarriage.
NCT03165136
Cohort of Patients Presenting Unexplained Recurrent Miscarriages and Identification of Early Miscarriage Recidivism Factors
NCT05557201
Detection of Bleeding Disorders Diagnosed After Vaginal Delivery Complicated by Severe Postpartum Hemorrhage
NCT06970860
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The etiologies of Fetal Deaths In Utero (MFIU) are also described: placental abnormalities, funicular abnormalities, fetal-maternal haemorrhage, fetal abnormalities (malformations, aneuploidy, genetic abnormalities), infections (in particular strepto B, E. coli and toxoplasmosis).
Certain risk factors are not studied in terms of their influence on fetal loss: body mass index (BMI), existence of chronic pathologies (diabetes, thyroid diseases, depression, other chronic diseases, etc.). ..), uterine scarring, uterine endoscopic surgery ATCD, sterility treatment (induction of ovulation, procreation medical assistance (MPA) type insemination or IVF, 1st trimester bleeding, prenatal diagnosis procedure (amniocentesis or biopsy trophoblast).
population concerned: Patients who had a pregnancy loss between 15 and 22 SA between 2010 and 2015, listed thanks to the data sheets of the Western Brittany Perinatal Network
Main objective: To identify risk factors for pregnancy loss between 15 SA and 22 SA.
main endpoint: BMI, existence of chronic pathologies (diabetes, thyroid pathologies, depression, other chronic diseases .....), treatments, uterine scarring, antecedent of uterine endoscopic surgery, treatment of infertility (induction of ovulation, medical assistance in procreation (MPA) type insemination or IVF), first trimester bleeding, prenatal diagnosis procedure (amniocentesis or trophoblast biopsy).
Methodology: Retrospective multicenter case-control study. Pairing 1 case for 1 witnesses. Match with age, parity, number of fetuses (single or multiple pregnancy)
Statistics: A typical descriptive analysis will be performed (means and standard deviation, medians and quartiles, proportions). Comparisons will be performed univarially by a matched Chi-square for proportions, a paired Student T-test if normal distribution or a matched non-parametric test (matched Willcoxon test) if non-normal distribution. Then a multivariate analysis will be performed using conditional logistic regression.
Criteria for inclusion:
CAS:
* patients who had a pregnancy loss between 15 and 22 SA between 2010 and 2015
* having given birth in one of the maternities of Western Brittany
* listed during the mortality reviews of the perinatal network of Western Brittany.
WITNESSES:
* patients who have given birth (\> 37SA) of healthy children
* having given birth in one of the maternity of Western Brittany. Pairing: Age, parity, number of fetuses (single or multiple pregnancy). Pairing 1 case for 1 witnesses.
Listed at Brest CHRU
Exclusion criteria:
* Pregnancy loss after 22 weeks,
* medical or therapeutic interruptions of pregnancy, fetuses whose anatomopathology describes biometrics below 15SA, fetuses with chromosomal malformations or abnormalities diagnosed before pregnancy loss.
Number of patients: 101 cases, 101 controls. The number of cases identified is 101, and the number of controls is set at 101 (1: 1).
Expected benefits: This study will identify or suggest high-intensity risk factors (OR\> 4); but the study will not be powerful enough to identify possible factors of lesser intensity (OR \<2). These preliminary results will lead to the subsequent development of a prospective study adjusted to specific and quantified hypotheses in order to establish an adequate number of necessary subjects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients who had a pregnancy loss between 15 and 22 SA between 2010 and 2015
* having given birth in one of the maternities of Western Brittany
* listed during the mortality reviews of the perinatal network of Western Brittany.
WITNESSES:
* patients who have given birth (\> 37SA) of healthy children
* having given birth in one of the maternity of Western Brittany. Pairing: Age, parity, number of fetuses (single or multiple pregnancy). Pairing 1 case for 1 witnesses.
Listed at Brest CHRU
Exclusion Criteria
* medical or therapeutic interruptions of pregnancy,
* fetuses whose anatomopathology describes biometrics below 15SA,
* fetuses with chromosomal malformations or abnormalities diagnosed before pregnancy loss.
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne-Laure SALAUN
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Brest
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SALAUN Anne -Laure
Brest, , France
CHRU de Brest
Brest, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PEGREP (29BRC17.0056)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.